Biological Activity of IFN mAbs
(A) Experimental timeline: mAb administered i.p. at day 0; human IFNα administered i.d. on days 1, 3, 6, and 8. Ear thickness measured on all days (prior to cytokine injection) except for day 5.
(B) I.p.-administered IFN mAbs reduced IFNα-induced ear inflammation.
Significance calculated by two-way ANOVA, with ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, and ∗∗∗∗p ≤ 0.0001. Error bars denote SEM.